{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:53:30Z","timestamp":1792522410538,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.cellsig.2022.110446","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:43:52Z","timestamp":1660909432000},"page":"110446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["The mechanism of action and clinical value of PROTACs: A graphical review"],"prefix":"10.1016","volume":"99","author":[{"given":"Harriet","family":"Graham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2022.110446_bb0005","doi-asserted-by":"crossref","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"15","key":"10.1016\/j.cellsig.2022.110446_bb0010","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Nat. Acad. Sci."},{"key":"10.1016\/j.cellsig.2022.110446_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/978-981-15-1025-0_19","article-title":"Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs","volume":"1217","author":"Gong","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"12","key":"10.1016\/j.cellsig.2022.110446_bb0020","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-cancerbio-030617-050430","article-title":"Proteolysis-targeting chimeras: harnessing the ubiquitin-proteasome system to induce degradation of specific target proteins","volume":"2","author":"Coleman","year":"2018","journal-title":"Ann. Rev. Cancer Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.cellsig.2022.110446_bb0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"issue":"6330","key":"10.1016\/j.cellsig.2022.110446_bb0045","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1126\/science.aam7340","article-title":"Waste disposal-An attractive strategy for cancer therapy","volume":"355","author":"Salami","year":"2017","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.cellsig.2022.110446_bb0050","doi-asserted-by":"crossref","first-page":"10726","DOI":"10.1021\/acs.jmedchem.0c00507","article-title":"Medicinal chemistry strategies for the development of kinase inhibitors targeting point mutations","volume":"63","author":"Lu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.cellsig.2022.110446_bb0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"4","key":"10.1016\/j.cellsig.2022.110446_bb0060","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1021\/jm2010332","article-title":"Rational approaches to improving selectivity in drug design","volume":"55","author":"Huggins","year":"2012","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.cellsig.2022.110446_bb0065","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nchembio.2538","article-title":"Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation","volume":"14","author":"Olson","year":"2018","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.cellsig.2022.110446_bb0070","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.cellsig.2022.110446_bb0075","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0080","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-019-11429-w","article-title":"Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations","volume":"10","author":"de Wispelaere","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.cellsig.2022.110446_bb0085","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10822-019-00197-w","article-title":"Elucidating the druggability of the human proteome with eFindSite","volume":"33","author":"Kana","year":"2019","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"9","key":"10.1016\/j.cellsig.2022.110446_bb0090","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nrd892","article-title":"The druggable genome","volume":"1","author":"Groom","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","article-title":"Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead","volume":"25","author":"Bondeson","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.cellsig.2022.110446_bb0105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.chembiol.2019.12.006","article-title":"Exploring Targeted Degradation Strategy for Oncogenic KRAS(G12C)","volume":"27","author":"Zeng","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0115","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cellsig.2022.110446_bb0120","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1007\/s12035-021-02339-4","article-title":"The role of the ubiquitin proteasome system in glioma: analysis emphasizing the main molecular players and therapeutic strategies identified in glioblastoma multiforme","volume":"58","author":"Maksoud","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.cellsig.2022.110446_bb0125","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/CCO.0000000000000178","article-title":"Implications of ubiquitin ligases in castration-resistant prostate cancer","volume":"27","author":"Qi","year":"2015","journal-title":"Curr. Opin. Oncol."},{"issue":"7","key":"10.1016\/j.cellsig.2022.110446_bb0130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.cellsig.2022.110446_bb0135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/17460441.2019.1659242","article-title":"PROTACs- a game-changing technology","volume":"14","author":"Konstantinidou","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"issue":"13","key":"10.1016\/j.cellsig.2022.110446_bb0140","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bmcl.2019.04.030","article-title":"Proteolysis targeting chimeras (PROTACs) in \u2018beyond rule-of-five\u2019 chemical space: Recent progress and future challenges","volume":"29","author":"Edmondson","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.cellsig.2022.110446_bb0145","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1021\/acscentsci.9b00713","article-title":"Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs","volume":"5","author":"Pfaff","year":"2019","journal-title":"ACS Central Sci."},{"issue":"5","key":"10.1016\/j.cellsig.2022.110446_bb0150","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1021\/acschembio.2c00185","article-title":"Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins","volume":"17","author":"Gramespacher","year":"2022","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.cellsig.2022.110446_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: a strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682200208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865682200208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:08:33Z","timestamp":1760267313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089865682200208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"alternative-id":["S089865682200208X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110446","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The mechanism of action and clinical value of PROTACs: A graphical review","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2022.110446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110446"}}